<DOC>
	<DOCNO>NCT01049685</DOCNO>
	<brief_summary>Retrospective longitudinal cohort study 36 HIV naïve-treatment patient , start therapy lopinavir/ritonavir efavirenz ( LPV/r EFZ ) , follow-up 36 month . Primary endpoint : virological success ( HIV RNA &lt; 50 copies/mL ) first six month end study .</brief_summary>
	<brief_title>Lopinavir/Ritonavir Efavirenz First-line Antiretroviral Therapy</brief_title>
	<detailed_description>Background : Either LPV/r EFZ plus two nucleoside reverse-transcriptase inhibitor ( NRTIs ) recommend current guideline around world main background drug initial therapy human immunodeficiency virus type 1 ( HIV-1 ) infection . This indication base result clinical trial , patient participate study usually greatly motivated continue prescribe regimen , different `` real life '' . Therefore , clinical practice often reproduce publish result . Methods : A retrospective longitudinal cohort study perform 36 naïve-treatment patient , start therapy LPV/r EFZ , follow-up 36 month . The primary endpoint virological success ( HIV RNA &lt; 50 copies/mL ) first six month end study . Effectiveness examine compare time virological failure CD4 recovery .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>HIV1 infect naivetreatment patient use AntiRetroviral Agents past</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>HIV</keyword>
	<keyword>Antiretroviral Therapy , Highly Active</keyword>
	<keyword>Efavirenz</keyword>
	<keyword>Lopinavir</keyword>
	<keyword>Comparative Effectiveness Research</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>